Pharma Equity Group’s datterselskab (Reponex Pharmaceuticals A/S) har modtaget meddelelse om godkendelse af patent på behandling med datterselskabets sårhelende lægemiddelkombination.
October 31, 2023 06:57 ET
|
Pharma Equity Group A/S
31. oktober 2023 Selskabsmeddelelse nr. 41 Pharma Equity Group’s datterselskab (Reponex Pharmaceuticals A/S) har modtaget meddelelse om godkendelse af patent på behandling med datterselskabets...
Pharma Equity Group’s subsidiary company (Reponex Pharmaceuticals A/S) have received grant of US Patent for a method of treatment on its topical wound-healing composition.
October 31, 2023 06:57 ET
|
Pharma Equity Group A/S
31 October 2023 Announcement no. 41 Pharma Equity Group’s subsidiary company (Reponex Pharmaceuticals A/S) have received grant of US Patent for a method of treatment on its topical wound-healing...
Indkaldelse til ekstraordinær generalforsamling i Pharma Equity Group A/S
October 11, 2023 06:27 ET
|
Pharma Equity Group A/S
11. oktober 2023 Meddelelse nr. 40 Indkaldelse til ekstraordinær generalforsamling i Pharma Equity Group A/S ("Selskabet") 2. november 2023 kl. 15:00 (dansk tid) hos Wihlborgs kantinerSlotsmarken...
Notice convening the extraordinary general meeting of Pharma Equity Group A/S
October 11, 2023 06:27 ET
|
Pharma Equity Group A/S
11 October 2023 Announcement no. 40 Notice convening the extraordinary general meeting of Pharma Equity Group A/S (the "Company") November 2, 2023, at 3 PM CET at Wihlborg's CanteensSlotsmarken...
Status for Selskabets tilgodehavende fra Portinho S.A.
September 25, 2023 14:49 ET
|
Pharma Equity Group A/S
25. september 2023 Meddelelse nr. 39 Status for Selskabets tilgodehavende fra Portinho S.A. I det konsoliderede regnskab (med datterselskabet Reponex Pharmaceuticals A/S) pr. 30. juni 2023 har...
Status of the Company's receivables from Portinho S.A.
September 25, 2023 14:49 ET
|
Pharma Equity Group A/S
25. September 2023 Announcement no. 39 Status of the Company's receivables from Portinho S.A. In the consolidated financial statement (with the subsidiary Reponex Pharmaceuticals A/S) as of 30...
Consolidated interim report 1 January – 30 June 2023
August 16, 2023 02:19 ET
|
Pharma Equity Group A/S
16 August 2023 Announcement no. 38 Consolidated interim report 1 January – 30 June 2023 Key points (H1 2023) On 16 August 2023, the Board of Directors and Executive...
Pharma Equity Group’s datterselskab (Reponex Pharmaceuticals A/S) modtager USPTO meddelelse om udstedelse af patent på behandling med datterselskabets sårhelende lægemiddelkombination.
August 15, 2023 07:54 ET
|
Pharma Equity Group A/S
15. August 2023 Selskabsmeddelelse nr. 37 Pharma Equity Group’s datterselskab (Reponex Pharmaceuticals A/S) modtager USPTO meddelelse om udstedelse af patent på behandling med...
Pharma Equity Group’s subsidiary company (Reponex Pharmaceuticals A/S) receives USPTO Notice of Allowance for a method of treatment patent on its topical wound-healing composition.
August 15, 2023 07:54 ET
|
Pharma Equity Group A/S
15 August 2023 Announcement no. 37 Pharma Equity Group’s subsidiary company (Reponex Pharmaceuticals A/S) receives USPTO Notice of Allowance for a method of treatment patent on its topical...
Status på selskabets tilgodehavende hos Portinho S.A. med betalingsfrist den 1. juli 2023
June 30, 2023 11:56 ET
|
Pharma Equity Group A/S
30 juni 2023 Meddelelse nr. 36 Status på selskabets tilgodehavende hos Portinho S.A. med betalingsfrist den 1. juli 2023 I det konsoliderede regnskab (med...